These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 24780944)
41. Predictors of long-term outcome of functional dyspepsia and duodenal ulcer after successful Helicobacter pylori eradication--a 7-year follow-up study. Maconi G; Sainaghi M; Molteni M; Bosani M; Gallus S; Ricci G; Alvisi V; Porro GB Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):387-93. PubMed ID: 19182682 [TBL] [Abstract][Full Text] [Related]
42. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Zerbib F; Belhocine K; Simon M; Capdepont M; Mion F; Bruley des Varannes S; Galmiche JP Gut; 2012 Apr; 61(4):501-6. PubMed ID: 21997546 [TBL] [Abstract][Full Text] [Related]
43. Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux. Palmieri B; Merighi A; Corbascio D; Rottigni V; Fistetto G; Esposito A Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3272-8. PubMed ID: 24379055 [TBL] [Abstract][Full Text] [Related]
44. [Long-term course of reflux symptoms following Helicobacter pylori eradication]. Peitz U; Raps S; Plein K; Leodolter A; Hotz Dagger J; Malfertheiner P Dtsch Med Wochenschr; 2004 Mar; 129(13):671-5. PubMed ID: 15026962 [TBL] [Abstract][Full Text] [Related]
45. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Wang WH; Huang JQ; Zheng GF; Xia HH; Wong WM; Liu XG; Karlberg J; Wong BC Clin Gastroenterol Hepatol; 2007 Feb; 5(2):178-85; quiz 140. PubMed ID: 17174612 [TBL] [Abstract][Full Text] [Related]
46. [Treatment of postprandial discomfort syndrome in the elderly: a multi-centered prospective randomized controlled clinical study]. Wang GS; Xu L; Chen HT; Shi LP; Huang MJ; Xi L; Xu LS; Wang F; Li HY; Li S; Zhang YJ; Tan SY; Hong RT; Lyu NH; Ye M; Gan HT; Liu M; Wu BY; Zhonghua Nei Ke Za Zhi; 2020 Feb; 59(2):117-123. PubMed ID: 32074684 [No Abstract] [Full Text] [Related]
47. The efficacy of Combizym in the treatment of Chinese patients with dyspepsia: a multicenter, randomized, placebo-controlled and cross-over study: Shanghai Combizym Clinical Cooperative Group. Ran ZH; Yuan YZ; Li ZS; Wang JY; Zong CH; Xie WF; Zheng P; Chen SL; Zhan XB; Chen SY; Xiao SD J Dig Dis; 2009 Feb; 10(1):41-8. PubMed ID: 19236546 [TBL] [Abstract][Full Text] [Related]
48. [Combination therapy of azintamid and domperidone in functional dyspepsia: a randomised, double-blind, placebo-controlled trial]. Zhao L; Xu L; Li Q; Wang XD; Wang DM; Wang ZG Zhonghua Nei Ke Za Zhi; 2011 Mar; 50(3):212-5. PubMed ID: 21600084 [TBL] [Abstract][Full Text] [Related]
49. [Peppermint oil-caraway oil fixed combination in non-ulcer dyspepsia--comparison of the effects of enteric preparations]. Freise J; Köhler S Pharmazie; 1999 Mar; 54(3):210-5. PubMed ID: 10192108 [TBL] [Abstract][Full Text] [Related]
50. Comparison of metoclopramide oral tablets and solution in treatment of dysmotility-like dyspepsia. Banani SJ; Lankarani KB; Taghavi A; Bagheri MH; Sefidbakht S; Geramizadeh B Am J Health Syst Pharm; 2008 Jun; 65(11):1057-61. PubMed ID: 18499880 [TBL] [Abstract][Full Text] [Related]
51. Dyspepsia and dyspepsia subgroups in Japan: symptom profiles and experience with cisapride. Inoue M; Sekiguchi T; Harasawa S; Miwa T; Miyoshi A Scand J Gastroenterol Suppl; 1993; 195():36-8; discussion 38-9. PubMed ID: 8516656 [TBL] [Abstract][Full Text] [Related]
52. Women and functional dyspepsia. Napthali K; Koloski N; Walker MM; Talley NJ Womens Health (Lond); 2016; 12(2):241-50. PubMed ID: 26901578 [TBL] [Abstract][Full Text] [Related]
53. Functional dyspepsia versus other functional gastrointestinal disorders: a practical approach in Belgian general practices. Verhaeghe J; Jaecques N; Rombouts J; Spaepen W; Cardon E; Lebrun F; Meurant JP Scand J Gastroenterol Suppl; 1993; 195():25-34; discussion 34-5. PubMed ID: 8516655 [TBL] [Abstract][Full Text] [Related]
54. Classification of dyspepsia. Identification of independent symptom components in 7270 consecutive, unselected dyspepsia patients from general practice. Meineche-Schmidt V; Christensen E Scand J Gastroenterol; 1998 Dec; 33(12):1262-72. PubMed ID: 9930389 [TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of cinitapride in functional dyspepsia. Baqai MT; Malik MN; Ziauddin F J Pak Med Assoc; 2013 Jun; 63(6):747-51. PubMed ID: 23901678 [TBL] [Abstract][Full Text] [Related]
58. Functional Dyspepsia: Evaluation and Management. Mounsey A; Barzin A; Rietz A Am Fam Physician; 2020 Jan; 101(2):84-88. PubMed ID: 31939638 [TBL] [Abstract][Full Text] [Related]
59. Effect of clinician-patient communication on compliance with flupentixol-melitracen in functional dyspepsia patients. Yan XJ; Li WT; Chen X; Wang EM; Liu Q; Qiu HY; Cao ZJ; Chen SL World J Gastroenterol; 2015 Apr; 21(15):4652-9. PubMed ID: 25914475 [TBL] [Abstract][Full Text] [Related]
60. Predominant symptom behavior in patients with persistent dyspepsia during treatment. Laheij RJ; De Koning RW; Horrevorts AM; Rongen RJ; Rossum LG; Witteman EM; Hermsen JT; Jansen JB J Clin Gastroenterol; 2004 Jul; 38(6):490-5. PubMed ID: 15220683 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]